Fargnoli M C, Kostaki D, Piccioni A, Di Stefani A, Peris K
Department of Dermatology, University of L'Aquila, L'Aquila, Italy -
G Ital Dermatol Venereol. 2015 Jun;150(3):331-5. Epub 2014 Jun 30.
Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) is approved in Europe for the treatment of actinic keratosis and Bowen's disease, both intraepithelial forms of squamous cell carcinoma (SCC). A therapeutic effect of MAL-PDT has been recently suggested for superficial, microinvasive and well-differentiated cutaneous SCC. We describe the successful use of MAL-PDT in a recently observed patient with microinvasive SCC of the lower lip and review published data on the use of PDT with MAL or d-aminolevulinic acid (ALA) in cutaneous microinvasive SCC. A patient with a biopsy-proven recurrent microinvasive SCC of the lower lip was treated with 2 cycles of MAL-PDT. Complete clinical, dermoscopic and histopathological clearance was obtained after 2 cycles of MAL-PDT with an excellent cosmetic result and a sustained remission after 24-month follow-up. A review of the few studies reporting on the use of MAL-PDT or ALA-PDT for cutaneous microinvasive SCCs was carried out. MAL-PDT might represent a non-invasive treatment option for microinvasive SCC of the lower lip if patients are not eligible for surgery. Post-treatment histopathological confirmation and a long-term follow-up are strictly recommended.
在欧洲,含甲基氨基酮戊酸(MAL)的光动力疗法(PDT)已被批准用于治疗光化性角化病和鲍恩病,这两种均为上皮内型鳞状细胞癌(SCC)。最近有研究表明,MAL-PDT对浅表性、微侵袭性和高分化皮肤SCC具有治疗效果。我们描述了MAL-PDT在一名近期观察到的下唇微侵袭性SCC患者中的成功应用,并回顾了已发表的关于在皮肤微侵袭性SCC中使用MAL或δ-氨基酮戊酸(ALA)进行PDT治疗的数据。一名经活检证实为下唇复发性微侵袭性SCC的患者接受了2个周期的MAL-PDT治疗。经过2个周期的MAL-PDT治疗后,临床、皮肤镜和组织病理学完全清除,美容效果极佳,24个月随访后持续缓解。我们对少数关于使用MAL-PDT或ALA-PDT治疗皮肤微侵袭性SCC的研究进行了综述。如果患者不符合手术条件,MAL-PDT可能是下唇微侵袭性SCC的一种非侵入性治疗选择。强烈建议进行治疗后组织病理学确认和长期随访。